Angiogenesis and anti-angiogenesis in haematological diseases

Review article

Summary

While it is well established that the growth of solid tumours is angiogenesis-dependent, it had assumed that leukemias and other haematological malignancies were not. The role of angiogenesis in growth and survival of these tumours has only been realised in the past 10 years. This review summarises the literature concerning the relationship between angiogenesis and disease progression of several haematological diseases. It is becoming increasingly evident that agents which interfere with blood vessels formation also block tumour progression and accordingly, anti-angiogenic therapy has gained much interest as a potential adjunct to conventional therapy for many haematological tumours.

Keywords

Angiogenesis Anti-angiogenesis Haematological malignancies 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1: 27–31, 1995PubMedCrossRefGoogle Scholar
  2. Ribatti D, Nico B, Crivellato E, et al. The history of the angiogenic switch concept. Leukemia, 21: 44–52, 2007PubMedCrossRefGoogle Scholar
  3. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia, 20: 193–199, 2006PubMedCrossRefGoogle Scholar
  4. Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene, 25: 4257–4266, 2006PubMedCrossRefGoogle Scholar
  5. Scavelli C, Nico B, Cirulli T, et al. Vasculogenic mimicry by bone marrow macrophages in patient with multiple myeloma. Oncogene (in press)Google Scholar
  6. Nico B, Mangieri D, Crivellato E, et al. Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev (in press)Google Scholar
  7. Ria R, Roccaro AM, Merchionne F, et al. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia, 17: 1961–1966, 2003PubMedCrossRefGoogle Scholar
  8. Ribatti D, Vacca A. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia, 19: 1525–1531, 2005PubMedCrossRefGoogle Scholar
  9. Singhal S, Metha J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341: 1565–1571, 1999PubMedCrossRefGoogle Scholar
  10. Roccaro AM, Hideshima T, Richardson PG, et al. Bortezomib as an antitumor agent. Curr Pharm Biotechnol, 7: 441–448, 2006PubMedCrossRefGoogle Scholar
  11. Perez-Atayde AR, Sallan SE, Tedrow U. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphocytic leukemia. Am J Pathol, 150: 815–821, 1997PubMedGoogle Scholar
  12. Aguayo AR, Kantarajian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemia and myelodysplastic syndromes. Blood, 96: 2240–2245, 2000PubMedGoogle Scholar
  13. Aguayo AR, Estey E, Kantarajian T, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 94: 3717–3721, 1999PubMedGoogle Scholar
  14. Letilovic T, Vrhovac R, Verstovsek S, et al. Role of angiogenesis in chronic lymphocytic leukemia. Cancer, 107: 925–934, 2006PubMedCrossRefGoogle Scholar
  15. Molica S, Vacca A, Ribatti D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lumphocytic leukemia. Blood, 100: 3344–3351, 2002PubMedCrossRefGoogle Scholar
  16. Shanafelt TD, Kay NE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol, 33: 174–185, 2006PubMedCrossRefGoogle Scholar
  17. Molica S, Vacca A, Tucci L, et al. Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy. Haematologica, 90: 698–700, 2005PubMedGoogle Scholar
  18. Rabtish W, Sperr WR, Lechner K, et al. Bone marrow microvessel density and its prognostic significate in AML. Leuk Lymphoma, 45: 1369–1373, 2004CrossRefGoogle Scholar
  19. Loges S, Heil G, Bruweleit M, et al. Analysis of concerted expression of angiogenic growth factors in acute myleoid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol, 23: 1109–1117, 2005PubMedCrossRefGoogle Scholar
  20. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogeneous leukemias: therapy with sequential 1-beta-D-arabinofuranosylcytosine, mitoxantrone and bevacizumab. Clin Cancer Res, 10: 3577–3585, 2004PubMedCrossRefGoogle Scholar
  21. Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biological activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood, 102: 795–801, 2003PubMedCrossRefGoogle Scholar
  22. Levis M, Pham R, Smith BD, et al. In vitro studies of a FM inhibitor combined with chemotherapy of administration is important to achieve synergistic cytosolic effects. Blood, 194: 1145–1150, 2004CrossRefGoogle Scholar
  23. Koster A, Raemaekers JMM. Angiogenesis in malignant lymphoma. Curr Opin Oncol, 17: 611–616, 2005PubMedCrossRefGoogle Scholar
  24. Ribatti D, Vacca A, Nico B, et al. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphoma. An immunohistochemical and ultrastructural study. Eur J Haematol, 56: 45–53, 1996PubMedGoogle Scholar
  25. Vacca A, Moretti S, Ribatti D, et al. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinase-2 and -9. Eur J Cancer, 33, 1685–1692, 1997PubMedCrossRefGoogle Scholar
  26. Bertolini F, Fusetti L, Mancuso P, et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non–Hodgkin lymphoma. Blood, 96: 282–287, 2000PubMedGoogle Scholar
  27. Noren-Nystrom U, Eriksson M, Eriksson B, et al. Antitumor activity of the angiogenesis inhibitor TNP-470 on a murine lymphoma/leukemia cells in vivo and in vitro. Exp Hematol, 31: 143–149, 2003PubMedCrossRefGoogle Scholar
  28. Kaufmann H, Raeder M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood, 104: 2269–2271, 2004PubMedCrossRefGoogle Scholar
  29. Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia, 19: 1993–1995, 2005PubMedCrossRefGoogle Scholar
  30. Tobinai K. Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int J Clin Oncol, 12: 318–326, 2007PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Human Anatomy and HistologyUniversity of Bari Medical SchoolBariItaly
  2. 2.Department of Internal Medicine and Clinical OncologyUniversity of Bari Medical SchoolBariItaly

Personalised recommendations